| Literature DB >> 36165630 |
J Chase McNeil1, Lauren M Sommer1, Jesus G Vallejo1, Kristina G Hulten1, Sheldon L Kaplan1, Anthony R Flores2.
Abstract
Ceftaroline represents an attractive therapy option for methicillin-resistant Staphylococcus aureus (MRSA). Little data is available, however, regarding the frequency of reduced susceptibility (RS) to ceftaroline among pediatric MRSA infections. We screened invasive MRSA isolates at a tertiary children's hospital for ceftaroline RS. Ceftaroline RS occurred in 2.9% of isolates and only among health care associated infections. Ceftaroline RS isolates were more often clindamycin-resistant. Sequencing data indicated the predominance of the CC5 lineage among ceftaroline RS isolates.Entities:
Keywords: MRSA; ceftaroline; health care associated; invasive; mecR; pediatric; resistance
Mesh:
Substances:
Year: 2022 PMID: 36165630 PMCID: PMC9578395 DOI: 10.1128/aac.00745-22
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.938